{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:03:11Z","timestamp":1793199791606,"version":"4.5.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK120515"],"award-info":[{"award-number":["P30 DK120515"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23 DK129776"],"award-info":[{"award-number":["K23 DK129776"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["ICX002027A"],"award-info":[{"award-number":["ICX002027A"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["NIDDK P30 DK 56338"],"award-info":[{"award-number":["NIDDK P30 DK 56338"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP220127"],"award-info":[{"award-number":["RP220127"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","gastrojournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1053\/j.gastro.2023.09.047","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T02:02:03Z","timestamp":1696557723000},"page":"267-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"title":["Evolving Concepts in Helicobacter pylori Management"],"prefix":"10.1053","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-0388","authenticated-orcid":false,"given":"Steven F.","family":"Moss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailja C.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi C.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5964-7579","authenticated-orcid":false,"given":"Hashem B.","family":"El-Serag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2023.09.047_bib1","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41572-023-00431-8","article-title":"Helicobacter pylori infection","volume":"9","author":"Malfertheiner","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1053\/j.gastro.2023.09.047_bib3","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1053\/j.gastro.2010.10.037","article-title":"Helicobacter pylori and esophageal disease: wake-up call?","volume":"6","author":"Blaser","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib4","article-title":"Helicobacter pylori eradication for the prevention of gastric neoplasia","volume":"7","author":"Ford","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2023.09.047_bib5","first-page":"243","article-title":"Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands","volume":"70","author":"Chiang","year":"2021","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.09.047_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009507","article-title":"Helicobacter pylori eradication improves the quality of life regardless of the treatment outcome: a multicenter prospective cohort study","volume":"96","author":"Taguchi","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.gastro.2023.09.047_bib7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.09.047_bib8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.09.047_bib9","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1007\/s10620-021-07323-5","article-title":"Pitfalls of physician-directed treatment of Helicobacter pylori: results from two phase 3 clinical trials and real-world prescribing data","volume":"67","author":"Howden","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.09.047_bib10","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/s41598-023-28200-3","article-title":"Diagnosis and treatment patterns among patients with newly diagnosed Helicobacter pylori infection in the United States 2016-2019","volume":"13","author":"Shah","year":"2023","journal-title":"Sci Rep"},{"key":"10.1053\/j.gastro.2023.09.047_bib11","doi-asserted-by":"crossref","first-page":"e2089","DOI":"10.1093\/milmed\/usac428","article-title":"Helicobacter pylori treatment regimen selection and eradication rates across Department of Defense patients for fiscal years 2016-2018","volume":"188","author":"Junga","year":"2023","journal-title":"Mil Med"},{"key":"10.1053\/j.gastro.2023.09.047_bib12","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1053\/j.gastro.2020.07.049","article-title":"Population-based analysis of differences in gastric cancer incidence among races and ethnicities in individuals age 50 years and older","volume":"159","author":"Shah","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib14","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.cgh.2021.09.039","article-title":"An approach to the primary and secondary prevention of gastric cancer in the United States","volume":"20","author":"Huang","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.gastro.2018.04.026","article-title":"Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality: a meta-analysis and systematic review","volume":"155","author":"Zhang","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","article-title":"Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib17","article-title":"Helicobacter pylori burden in the United States according to individual demographics and geography: a nationwide analysis of the veterans healthcare system [published online ahead of print May 26, 2023]","author":"Shah","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib18","first-page":"510","article-title":"Seroprevalence of Helicobacter pylori in New York City populations originating in East Asia","volume":"82","author":"Perez-Perez","year":"2005","journal-title":"J\u00a0Urban Health"},{"key":"10.1053\/j.gastro.2023.09.047_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.gastro.2023.09.047_bib20","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"de Martel","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.gastro.2023.09.047_bib21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ijc.28999","article-title":"Global burden of gastric cancer attributable to Helicobacter pylori","volume":"136","author":"Plummer","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1053\/j.gastro.2023.09.047_bib22","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1016\/j.cgh.2023.01.037","article-title":"Epidemiology of gastric malignancies 2000\u20132018 according to histology: a population-based analysis of incidence and temporal trends","volume":"21","author":"Rustgi","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/gut.49.3.347","article-title":"Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts","volume":"49","year":"2001","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.09.047_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10552-010-9707-2","article-title":"Helicobacter pylori infection and gastric cardia cancer: systematic review and meta-analysis","volume":"22","author":"Cavaleiro-Pinto","year":"2011","journal-title":"Cancer Causes Control"},{"key":"10.1053\/j.gastro.2023.09.047_bib25","first-page":"1488","article-title":"Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction","volume":"71","author":"Sugano","year":"2022","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.09.047_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1940-6207.CAPR-21-0426","article-title":"Prediction models for gastric cancer risk in the general population: a systematic review","volume":"15","author":"Gu","year":"2022","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1053\/j.gastro.2023.09.047_bib27","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2016.01.028","article-title":"Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis","volume":"150","author":"Lee","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib28","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/MEG.0000000000001740","article-title":"Effectiveness of Helicobacter pylori eradication in preventing metachronous gastric cancer and preneoplastic lesions. A systematic review and meta-analysis","volume":"32","author":"Khan","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib29","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMoa1708423","article-title":"Helicobacter pylori therapy for the prevention of metachronous gastric cancer","volume":"378","author":"Choi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2023.09.047_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/j.gastro.2022.03.039","article-title":"Effect of Helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow-up","volume":"163","author":"Yan","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1053\/j.gastro.2023.04.026","article-title":"Effect of Helicobacter pylori eradication therapy on the incidence of noncardia gastric adenocarcinoma in a large diverse population in the United States","volume":"165","author":"Li","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1053\/j.gastro.2019.10.019","article-title":"Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study","volume":"158","author":"Kumar","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/gutjnl-2015-309197","article-title":"A\u00a0large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication","volume":"65","author":"Pan","year":"2016","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.09.047_bib34","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.bpg.2014.10.003","article-title":"The fight against gastric cancer - the IARC Working Group report","volume":"28","author":"Herrero","year":"2014","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2023.09.047_bib35","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3748\/wjg.v26.i10.995","article-title":"Global whole family based-Helicobacter pylori eradication strategy to prevent its related diseases and gastric cancer","volume":"26","author":"Ding","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.09.047_bib36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/gutjnl-2021-325630","article-title":"Chinese consensus report on family-based Helicobacter pylori infection control and management (2021 edition)","volume":"71","author":"Ding","year":"2022","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.09.047_bib37","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.cgh.2018.03.013","article-title":"Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States","volume":"16","author":"El-Serag","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12793","article-title":"Whole family-based Helicobacter pylori eradication is a superior strategy to single-infected patient treatment approach: a systematic review and meta-analysis","volume":"26","author":"Zhao","year":"2021","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2023.09.047_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ijc.23864","article-title":"Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results","volume":"124","author":"Yeh","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1053\/j.gastro.2023.09.047_bib40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1017\/S0266462307080117","article-title":"Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese","volume":"24","author":"Xie","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"issue":"Suppl 7","key":"10.1053\/j.gastro.2023.09.047_bib41","first-page":"13","article-title":"Cost-effectiveness of Helicobacter pylori screening and treatment for gastric cancer in Hong Kong: a decision analytic approach","volume":"20","author":"Wong","year":"2014","journal-title":"Hong Kong Med J"},{"key":"10.1053\/j.gastro.2023.09.047_bib42","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s10620-022-07795-z","article-title":"A\u00a0population-based Helicobacter pylori eradication strategy is more cost-effective than endoscopic screening","volume":"68","author":"Kowada","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.09.047_bib43","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0140-6736(96)01501-2","article-title":"Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials","volume":"348","author":"Parsonnet","year":"1996","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2023.09.047_bib44","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/archinte.159.2.142","article-title":"Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer","volume":"159","author":"Fendrick","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.gastro.2023.09.047_bib45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacr.2009.01.022","article-title":"Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada","volume":"6","author":"Xie","year":"2009","journal-title":"J\u00a0Am Coll Radiol"},{"key":"10.1053\/j.gastro.2023.09.047_bib46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/archinte.162.2.163","article-title":"Cost-effectiveness of a single colonoscopy in screening for colorectal cancer","volume":"162","author":"Sonnenberg","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.gastro.2023.09.047_bib47","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10552-019-01178-y","article-title":"Cost-effectiveness of breast cancer screening in the National Breast and Cervical Cancer Early Detection Program","volume":"30","author":"Rim","year":"2019","journal-title":"Cancer Causes Control"},{"key":"10.1053\/j.gastro.2023.09.047_bib48","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa1312547","article-title":"Cost-effectiveness of CT screening in the National Lung Screening Trial","volume":"371","author":"Black","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2023.09.047_bib49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1523-5378.1999.98057.x","article-title":"Helicobacter pylori and gastric cancer: what are the benefits of screening only for the CagA phenotype of H. pylori?","volume":"4","author":"Harris","year":"1999","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2023.09.047_bib50","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/gutjnl-2014-308588","article-title":"Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis","volume":"65","author":"Yeh","year":"2016","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.09.047_bib51","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.21037\/jgo-21-911","article-title":"Cost-effectiveness of screening with polymerase chain reaction for Helicobacter pylori to prevent gastric cancer and peptic ulcers","volume":"13","author":"Oh","year":"2022","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1053\/j.gastro.2023.09.047_bib52","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10620-022-07587-5","article-title":"Missed opportunities for screening or surveillance among patients with newly diagnosed non-cardia gastric adenocarcinoma","volume":"68","author":"Tan","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.09.047_bib53","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1158\/1055-9965.EPI-13-1057","article-title":"Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention","volume":"23","author":"Karimi","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.gastro.2023.09.047_bib54","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.cgh.2022.10.012","article-title":"Socioeconomic status and ethnic enclave as risk factors for gastric adenocarcinoma in Hispanic and Asian Americans, a California Cancer Registry analysis","volume":"21","author":"Wang","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib55","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.cgh.2022.10.009","article-title":"The predictive performance of contemporary guideline recommendations for Helicobacter pylori testing in a United States population","volume":"21","author":"Nguyen Wenker","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib56","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/jnci\/92.23.1881","article-title":"Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy","volume":"92","author":"Correa","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1053\/j.gastro.2023.09.047_bib57","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/gutjnl-2011-300154","article-title":"Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions","volume":"61","author":"Wong","year":"2012","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.09.047_bib58","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1136\/gutjnl-2020-322368","article-title":"Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus","volume":"69","author":"Liou","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.09.047_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7060","article-title":"The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model","volume":"7","author":"Roderick","year":"2003","journal-title":"Health Technol Assess"},{"key":"10.1053\/j.gastro.2023.09.047_bib60","first-page":"401","article-title":"Which test is best for Helicobacter pylori? A cost-effectiveness model using decision analysis","volume":"57","author":"Elwyn","year":"2007","journal-title":"Br J Gen Pract"},{"key":"10.1053\/j.gastro.2023.09.047_bib61","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1046\/j.1365-2036.2002.01204.x","article-title":"The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial","volume":"16","author":"Mason","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.09.047_bib62","article-title":"Prediction of chronic atrophic gastritis and gastric neoplasms by serum pepsinogen assay: a systematic review and meta-analysis of diagnostic test accuracy","volume":"8","author":"Bang","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1053\/j.gastro.2023.09.047_bib63","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7087232","article-title":"The value of pepsinogen in GC screening: a systematic review and meta-analysis","volume":"2019","author":"Liu","year":"2019","journal-title":"Gastroenterol Res Pract"},{"key":"10.1053\/j.gastro.2023.09.047_bib64","article-title":"Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis","volume":"10","author":"Huang","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2023.09.047_bib65","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cgh.2021.01.009","article-title":"Pepsinogens and gastrin demonstrate low discrimination for gastric precancerous lesions in a multi-ethnic United States cohort","volume":"20","author":"Huang","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib66","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.gie.2011.05.001","article-title":"Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis","volume":"74","author":"Gupta","year":"2011","journal-title":"Gastrointest Endosc"},{"key":"10.1053\/j.gastro.2023.09.047_bib67","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1053\/j.gastro.2018.05.026","article-title":"Cost effectiveness of gastric cancer screening according to race and ethnicity","volume":"155","author":"Saumoy","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/2050640617722902","article-title":"Endoscopic screening for gastric cancer: a cost-utility analysis for countries with an intermediate gastric cancer risk","volume":"6","author":"Areia","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"10.1053\/j.gastro.2023.09.047_bib69","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1053\/j.gastro.2019.12.003","article-title":"AGA clinical practice guidelines on management of gastric intestinal metaplasia","volume":"158","author":"Gupta","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib70","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/a-0859-1883","volume":"51","author":"Pimentel-Nunes","year":"2019","journal-title":"Endoscopy"},{"key":"10.1053\/j.gastro.2023.09.047_bib71","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/gutjnl-2018-318126","article-title":"British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma","volume":"68","author":"Banks","year":"2019","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.09.047_bib72","article-title":"The clinical impact and cost-effectiveness of surveillance of incidentally detected gastric intestinal metaplasia: a microsimulation analysis [published online ahead of print June 9, 2023]","author":"Thiruvengadam","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib74","series-title":"Evaluation of post-treatment confirmatory testing and eradication rates of Helicobacter pylori in a large, diverse, community-based population [abstract]","author":"Li","year":"2023"},{"key":"10.1053\/j.gastro.2023.09.047_bib75","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231167284","article-title":"Global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of Helicobacter pylori infection","volume":"16","author":"Moss","year":"2023","journal-title":"Ther Adv Gastro"},{"key":"10.1053\/j.gastro.2023.09.047_bib76","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib77","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.14309\/ajg.0000000000001828","article-title":"Helicobacter pylori antibiotic resistance in the United States between 2011 and 2021: a systematic review and meta-analysis","volume":"117","author":"Ho","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.09.047_bib78","doi-asserted-by":"crossref","first-page":"524","DOI":"10.14309\/ajg.0000000000001659","article-title":"Antimicrobial susceptibility testing for Helicobacter pylori is now widely available: when, how, why","volume":"117","author":"Graham","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.09.047_bib79","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2019.04.011","article-title":"Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics","volume":"157","author":"Fallone","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib80","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib81","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.09.047_bib82","doi-asserted-by":"crossref","first-page":"795","DOI":"10.7326\/M19-3734","article-title":"Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: a double-blind, randomized, controlled trial","volume":"172","author":"Graham","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2023.09.047_bib83","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1007\/s10620-019-05694-4","article-title":"Retrospective analysis confirms tetracycline quadruple as best Helicobacter pylori regimen in the USA","volume":"64","author":"Alsamman","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.09.047_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189888","article-title":"Meta-analysis: high-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment","volume":"13","author":"Ji","year":"2018","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2023.09.047_bib85","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cgh.2020.03.059","article-title":"Low rates of retesting for eradication of Helicobacter pylori infection after treatment in the Veterans Health Administration","volume":"19","author":"Kumar","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib86","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cgh.2021.03.026","article-title":"Primer for development of guidelines for Helicobacter pylori therapy using antimicrobial stewardship","volume":"20","author":"Graham","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.913436","article-title":"Empirical vs. susceptibility-guided treatment of Helicobacter pylori infection: a systematic review and meta-analysis","volume":"13","author":"Nyssen","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1053\/j.gastro.2023.09.047_bib88","article-title":"Tailored therapy for Helicobacter pylori eradication: a systematic review and meta-analysis","volume":"13","author":"Ma","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1053\/j.gastro.2023.09.047_bib89","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/cpt.2015","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and proton pump inhibitor dosing","volume":"109","author":"Lima","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.09.047_bib90","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1046\/j.1365-2036.2003.01759.x","article-title":"Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies","volume":"18","author":"Lamouliatte","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.09.047_bib91","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1053\/j.gastro.2018.06.047","article-title":"Efficacies of genotypic resistance-guided vs empirical therapy for refractory Helicobacter pylori infection","volume":"155","author":"Liou","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib92","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1053\/j.gastro.2020.11.059","article-title":"AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review","volume":"160","author":"Shah","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib93","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41575-021-00449-x","article-title":"Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications","volume":"18","author":"Tshibangu-Kabamba","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib94","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1016\/j.cgh.2023.02.026","article-title":"Helicobacter pylori antimicrobial resistance in a pediatric population from the New England region of the United States","volume":"21","author":"Herzlinger","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib95","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12873","article-title":"Need for standardization and harmonization of Helicobacter pylori antimicrobial susceptibility testing","volume":"27","author":"Li","year":"2022","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2023.09.047_bib96","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cll.2022.02.007","article-title":"The successes and challenges of SARS-CoV-2 molecular testing in the United States","volume":"42","author":"Dien Bard","year":"2022","journal-title":"Clin Lab Med"},{"key":"10.1053\/j.gastro.2023.09.047_bib97","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2468-1253(23)00097-3","article-title":"Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials","volume":"8","author":"Chen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib98","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/antibiotics10040437","article-title":"Next generation sequencing for the prediction of the antibiotic resistance in Helicobacter pylori: a literature review","volume":"10","author":"Saracino","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1053\/j.gastro.2023.09.047_bib99","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1053\/j.gastro.2021.02.014","article-title":"Impact of antimicrobial resistance rates on eradication of Helicobacter pylori in a US population","volume":"160","author":"Argueta","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib100","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12790","article-title":"Advantage of 16S rRNA amplicon sequencing in Helicobacter pylori diagnosis","volume":"26","author":"Gantuya","year":"2021","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2023.09.047_bib101","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1053\/j.gastro.2021.07.012","article-title":"Comparison of culture with antibiogram to next-generation sequencing using bacterial isolates and formalin-fixed, paraffin-embedded gastric biopsies","volume":"161","author":"Hulten","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib102","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1053\/j.gastro.2022.02.027","article-title":"Comparable results of Helicobacter pylori antibiotic resistance testing of stools vs gastric biopsies using next-generation sequencing","volume":"162","author":"Moss","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib103","doi-asserted-by":"crossref","first-page":"360","DOI":"10.14309\/ajg.0000000000002085","article-title":"Tailored treatment based on Helicobacter pylori genetic markers of resistance is associated with higher eradication success","volume":"118","author":"Cummings","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.09.047_bib104","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0016-5085(96)70056-2","article-title":"The effect of\u00a0environmental pH on the proton motive force of Helicobacter pylori","volume":"111","author":"Meyer-Rosberg","year":"1996","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2023.09.047_bib105","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1136\/gut.43.2008.S56","article-title":"The life and death of Helicobacter pylori","volume":"43","author":"Scott","year":"1998","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.09.047_bib106","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/apt.12059","article-title":"The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin","volume":"36","author":"Marcus","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.09.047_bib107","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0016-5085(98)70633-X","article-title":"The role of internal urease in acid resistance of Helicobacter pylori","volume":"114","author":"Scott","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib108","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/39.1.5","article-title":"The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection","volume":"39","author":"Erah","year":"1997","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1053\/j.gastro.2023.09.047_bib109","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/apt.12014","article-title":"Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype","volume":"36","author":"Sugimoto","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.09.047_bib110","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.cgh.2017.09.033","article-title":"Interchangeable use of proton pump inhibitors based on relative potency","volume":"16","author":"Graham","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib111","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2021.07.043","article-title":"Host genetic determinants associated with Helicobacter pylori eradication treatment failure: a systematic review and\u00a0meta-analysis","volume":"161","author":"Shah","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib112","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.09.047_bib113","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.09.047_bib114","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/ctg.2015.18","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese\/non-Japanese subjects","volume":"6","author":"Sakurai","year":"2015","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1053\/j.gastro.2023.09.047_bib115","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.13325","article-title":"Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult\u00a0male subjects--a randomised open-label cross-over study","volume":"42","author":"Sakurai","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.09.047_bib116","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/apt.15641","article-title":"Randomised trial of acid inhibition by vonoprazan 10\/20 mg once daily vs rabeprazole 10\/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study)","volume":"51","author":"Takeuchi","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.09.047_bib117","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.14309\/ajg.0000000000001735","article-title":"Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects","volume":"117","author":"Laine","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.09.047_bib118","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5056\/jnm18029","article-title":"Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases","volume":"24","author":"Oshima","year":"2018","journal-title":"J\u00a0Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2023.09.047_bib119","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12970","article-title":"Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: a multicenter randomized controlled trial in China","volume":"28","author":"Hu","year":"2023","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2023.09.047_bib120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1128\/AAC.17.2.199","article-title":"Absorption and disposition kinetics of amoxicillin in normal human subjects","volume":"17","author":"Arancibia","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.gastro.2023.09.047_bib121","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/apt.17526","article-title":"Physiologically-based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection","volume":"58","author":"Howden","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2023.09.047_bib122","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1007\/s10620-021-07320-8","article-title":"Helicobacter pylori management is associated with predominantly negative patient experiences: results from a focused qualitative analysis","volume":"67","author":"Shah","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.09.047_bib123","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.gastro.2021.10.048","article-title":"How we approach difficult to eradicate Helicobacter pylori","volume":"162","author":"Argueta","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2023.09.047_bib124","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12860","article-title":"Impact of smoking on the eradication of Helicobacter pylori","volume":"27","author":"Yu","year":"2022","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2023.09.047_bib125","first-page":"1273","article-title":"Unidentified curved bacilli on gastric epithelium in active chronic gastritis","volume":"8336","author":"Warren","year":"1983","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2023.09.047_bib126","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrgastro.2017.57","article-title":"Helicobacter pylori infection and antibiotic resistance: a WHO high priority?","volume":"14","author":"Dang","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2023.09.047_bib127","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12630","article-title":"Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg)","volume":"24","author":"McNicholl","year":"2019","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2023.09.047_bib128","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1020326005465","article-title":"A\u00a0simulation to evaluate screening for Helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers","volume":"5","author":"Davies","year":"2002","journal-title":"Health Care Manag Sci"},{"key":"10.1053\/j.gastro.2023.09.047_bib129","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12879-017-2259-2","article-title":"A\u00a0screening program to test and treat for Helicobacter pylori infection: cost-utility analysis by age, sex and ethnicity","volume":"17","author":"Teng","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1053\/j.gastro.2023.09.047_bib130","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/1055-9965.EPI-06-0758","article-title":"Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer","volume":"16","author":"Lee","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.gastro.2023.09.047_bib131","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.3748\/wjg.14.3021","article-title":"Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a Markov model","volume":"14","author":"Xie","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2023.09.047_bib132","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1007\/s10620-019-05910-1","article-title":"Cost-effectiveness analysis of Helicobacter pylori eradication therapy for prevention of gastric cancer: a Markov model","volume":"65","author":"Han","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2023.09.047_bib133","doi-asserted-by":"crossref","first-page":"9986","DOI":"10.3390\/ijerph19169986","article-title":"Cost-effectiveness analysis of the Helicobacter pylori screening programme in an asymptomatic population in China","volume":"19","author":"Feng","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1053\/j.gastro.2023.09.047_bib134","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1136\/gutjnl-2021-325948","article-title":"Nationwide gastric cancer prevention in China, 2021-2035: a decision analysis on effect, affordability and cost-effectiveness optimisation","volume":"71","author":"Wang","year":"2022","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2023.09.047_bib135","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3390\/curroncol30010086","article-title":"Cost-effectiveness analysis of Hp and new gastric cancer screening scoring system for screening and prevention of gastric cancer","volume":"30","author":"Zheng","year":"2023","journal-title":"Curr Oncol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508523050837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508523050837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T21:56:48Z","timestamp":1730325408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508523050837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":133,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0016508523050837"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2023.09.047","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving Concepts in Helicobacter pylori Management","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2023.09.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}